<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-147038</identifier>
<setSpec>0210-5705</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment safety in inflammatory bowel disease</dc:title>
<dc:description xml:lang="en">Treatment of inflammatory bowel disease is increasingly complex and effective. However safety continues to be a concern. In Digestive Diseases Week 2006, evidence was presented suggesting that a) azathioprine and mercaptopurine increase the risk of cervical dysplasia; b) corticoids are associated with a considerable risk of infections &#150; in one study with candidiasis; c) infliximab, although safer than corticoids, is associated with serious risks (including mortality). There is evidence to suggest that an active policy of vaccinations in patients with inflammatory bowel disease should be developed. The data reported confirm that mesalazine and azathioprine (and probably infliximab) are safe during pregnancy. Other collateral effects with adalimumab and certolizumab have not been described, which &#150; within a one-year time period &#150; seem reasonably safe, although a policy of active pharmacovigilance is required (AU)</dc:description>
<dc:creator>Gomollón, Fernando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tratamiento de las enfermedades inflamatorias intestinales es cada vez más complejo y eficaz. Sin embargo, preocupa considerablemente la seguridad. En la Digestive Disease Week (DDW) de 2006 se han presentado evidencias que sugieren que: a) es posible que la azatioprina y la mercaptopurina aumenten el riesgo de displasia de cuello de útero; b) los corticoides se asocian a un considerable riesgo de infecciones, en un estudio en concreto con la candidiasis, y c) el infliximab, aunque más seguro que los corticoides, se asocia con riesgos relevantes (incluso mortalidad). Hay datos que sugieren que hay que desarrollar una política activa de vacunaciones en los pacientes con enfermedad inflamatoria intestinal. Los datos comunicados confirman que la mesalazina y la azatioprina (y probablemente el infliximab) son seguras en el embarazo. No se han descrito otros efectos colaterales con adalimumab y certolizumab, que en el horizonte de un año parecen razonablemente seguros, aunque es precisa una política de farmacovigilancia activa (AU)</dc:description>
<dc:source>Gastroenterol Hepatol;29(supl.3): 45-51, nov. 2006.</dc:source>
<dc:identifier>ibc-147038</dc:identifier>
<dc:title xml:lang="es">Seguridad de los tratamientos en la enfermedad inflamatoria intestinal</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d23971^s22080</dc:subject>
<dc:subject>^d23973^s22054</dc:subject>
<dc:subject>^d54726</dc:subject>
<dc:subject>^d30150^s22066</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23695^s22067</dc:subject>
<dc:subject>^d23971^s22054</dc:subject>
<dc:subject>^d3250^s22049</dc:subject>
<dc:subject>^d23973^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23695^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d23695^s22080</dc:subject>
<dc:subject>^d23971^s22038</dc:subject>
<dc:subject>^d1394^s22073</dc:subject>
<dc:subject>^d23695^s22054</dc:subject>
<dc:subject>^d23973^s22038</dc:subject>
<dc:subject>^d54857^s22048</dc:subject>
<dc:type>article</dc:type>
<dc:date>200611</dc:date>
</metadata>
</record>
</ibecs-document>
